Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Treating insomnia: Current and investigational pharmacological approaches

Ebert, Bjarke, Wafford, Keith A., Deacon, Stephen · 2006 · Pharmacology & Therapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2005.04.014

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 153

  1. Åkerstedt, 1977, Psychophysiological circadian rhythms in women during 72 h of sleep deprivation, Waking Sleeping, 1, 387
  2. Amici, 2004, A serotonergic (5-HT2) receptor mechanism in the laterodorsal tegmental nucleus participates in regulating the pattern of rapid-eye-movement sleep occurrence in the rat, Brain Res, 996, 9, 10.1016/j.brainres.2003.09.026 · DOI
  3. Ancoli-Israel, 1999, Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects, Prim Care Companion J Clin Psychiatry, 1, 114, 10.4088/PCC.v01n0404 · DOI
  4. Arendt, 1997, Treatment of circadian rhythm disorders, Chronobiol Int, 14, 185, 10.3109/07420529709001155 · DOI
  5. Arendt, 1995, Melatonin and adjustment to phase shift, J Sleep Res, 4, 74, 10.1111/j.1365-2869.1995.tb00232.x · DOI
  6. Ator, 2000, Zaleplon and triazolam: drug discrimination, plasma levels, and self administration in baboons, Drug Alcohol Depend, 24, 55, 10.1016/S0376-8716(00)00123-X · DOI · Paper page
  7. Ator, 1986, Discriminative stimulus effects of atypical anxiolytics in baboons and rats, J Pharmacol Exp Ther, 237, 393
  8. Baker, 2005, Persistence of sleep–temperature coupling after suprachiasmatic nuclei lesions in rats, Am J Physiol Regul Integr Comp Physiol, 289, R827, 10.1152/ajpregu.00093.2005 · DOI
  9. Bateson, 2004, The benzodiazepine site of the GABAA receptor: an old target with new potential?, Sleep Med, 5, 9, 10.1016/S1389-9457(04)90002-0 · DOI
  10. Belelli, 2005, Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics, J Neurosci, 25, 11513, 10.1523/JNEUROSCI.2679-05.2005 · DOI · Paper page
  11. Benke, 1996, GABAA receptor subtypes differentiated by their gamma-subunit variants: prevalence, pharmacology and subunit architecture, Neuropharmacology, 35, 1413, 10.1016/S0028-3908(96)00068-8 · DOI
  12. Bianchi, 1990, Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena, Int Clin Psychopharmacol, 5, 139
  13. Bispink, 1990, Influence of melatonin on the sleep-independent component of prolactin secretion, J Pineal Res, 8, 97, 10.1111/j.1600-079X.1990.tb00669.x · DOI
  14. Blin, 2005, Zolpidem modified-release 12.5 mg has no residual effects on psychomotor performance and cognitive function in healthy adult subjects, Sleep, 28, A246
  15. Borbely, 1982, A two process model of sleep regulation, Hum Neurobiol, 1, 195
  16. Borbely, 1999, Sleep homeostasis and models of sleep regulation, J Biol Rhythms, 14, 557
  17. Borbely, 1985, Effect of benzodiazepine hypnotics on all-night sleep EEG spectra, Hum Neurobiol, 4, 189
  18. Brown, 2002, Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors, Br J Pharmacol, 136, 965, 10.1038/sj.bjp.0704795 · DOI · Paper page
  19. Brunello, 2000, Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment, Neuropsychobiology, 42, 107, 10.1159/000026680 · DOI
  20. Brunner, 1991, Effect of zolpidem on sleep and sleep EEG spectra in healthy young men, Psychopharmacology (Berlin), 104, 1, 10.1007/BF02244546 · DOI
  21. Brunner, 1993, Repeated partial sleep deprivation progressively changes in EEG during sleep and wakefulness, Sleep, 16, 100, 10.1093/sleep/16.2.100 · DOI · Paper page
  22. Cajochen, 1997, Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis, Am J Physiol, 272, R1189
  23. Chou, 2002, Afferents to the ventrolateral preoptic nucleus, J Neurosci, 22, 977, 10.1523/JNEUROSCI.22-03-00977.2002 · DOI · Paper page
  24. Danjou, 1999, A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening, Br J Clin Pharmacol, 48, 367, 10.1046/j.1365-2125.1999.00024.x · DOI
  25. Davies, 2000, Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors, Mol Pharmacol, 58, 756, 10.1124/mol.58.4.756 · DOI
  26. Deacon, 1995, Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans, Brain Res, 688, 77, 10.1016/0006-8993(95)96872-I · DOI · Paper page
  27. Deacon, 1996, Adapting to phase shifts: II. Effects of melatonin and conflicting light treatment, Physiol Behavior, 59, 675, 10.1016/0031-9384(95)02148-5 · DOI
  28. Deacon, 1994, Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans, Neurosci Lett, 178, 32, 10.1016/0304-3940(94)90282-8 · DOI
  29. Dijk, 1997, Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG, J Biol Rhythms, 12, 627, 10.1177/074873049701200618 · DOI · Paper page
  30. Dijk, 1994, Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans, Neurosci Lett, 166, 63, 10.1016/0304-3940(94)90841-9 · DOI · Paper page
  31. Dijk, 1989, All night spectral analysis of EEG sleep in young adult and middle-aged male subjects, Neurobiol Aging, 10, 677, 10.1016/0197-4580(89)90004-3 · DOI · Paper page
  32. Dijk, 1992, Circadian and sleep/wake dependent aspects of subjective alertness and cognitive performance, J Sleep Res, 1, 112, 10.1111/j.1365-2869.1992.tb00021.x · DOI · Paper page
  33. Dijk, 1999, Ageing and the circadian and homeostatic regulation of human sleep during forced desynchrony of rest, melatonin and temperature rhythms, J Physiol, 516, 611, 10.1111/j.1469-7793.1999.0611v.x · DOI · Paper page
  34. Dooley, 2000, Zaleplon: a review of its use in the treatment of insomnia, Drugs, 60, 413, 10.2165/00003495-200060020-00014 · DOI · Paper page
  35. Drake, 2003, Insomnia causes, consequences, and therapeutics: an overview, Depress Anxiety, 18, 163, 10.1002/da.10151 · DOI · Paper page
  36. Drake, 2004, Vulnerability to stress-related sleep disturbance and hyperarousal, Sleep, 27, 285, 10.1093/sleep/27.2.285 · DOI · Paper page
  37. Drosopoulos, 2005, Sleep enhances explicit recollection in recognition memory, Learn Mem, 12, 44, 10.1101/lm.83805 · DOI · Paper page
  38. Drover, 2004, Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone, Clin Pharmacokinet, 43, 227, 10.2165/00003088-200443040-00002 · DOI · Paper page
  39. Ebert, 1994, Molecular pharmacology of gamma-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta, and gamma receptor subunit combinations, Mol Pharmacol, 46, 957
  40. Elie, 1999, Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group, J Clin Psychiatry, 60, 536, 10.4088/JCP.v60n0806 · DOI · Paper page
  41. Erman, 2001, Sleep architecture and its relationship to insomnia, J Clin Psychiatry, 62, 9
  42. Erman, 2006, An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia, Sleep Med, 7, 17, 10.1016/j.sleep.2005.09.004 · DOI · Paper page
  43. Faulhaber, 1997, The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans, Psychopharmacology (Berlin), 130, 285, 10.1007/s002130050241 · DOI
  44. Feinberg, 2000, Effects of hypnotics on the sleep EEG of healthy young adults: new data and psychopharmacologic implications, J Psychiatr Res, 34, 423, 10.1016/S0022-3956(00)00038-8 · DOI
  45. Foster, 2004, In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, J Pharmacol Exp Ther, 311, 547, 10.1124/jpet.103.063487 · DOI
  46. Gaudreau, 2001, Age-related modifications of NREM sleep EEG: from childhood to middle age, J Sleep Res, 10, 165, 10.1046/j.1365-2869.2001.00252.x · DOI · Paper page
  47. Gaus, 2002, Ventrolateral preoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species, Neuroscience, 115, 285, 10.1016/S0306-4522(02)00308-1 · DOI · Paper page
  48. Griffiths, 1991, Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons, Psychopharmacology (Berlin), 103, 154, 10.1007/BF02244196 · DOI
  49. Griffiths, 2005, Ramelteon and triazolam in humans: behavioral effects and abuse potential, Sleep, 289, A44
  50. Hadingham, 1995, Expression and pharmacology of human GABAA receptors containing gamma 3 subunits, Eur J Pharmacol, 291, 301, 10.1016/0922-4106(95)90070-5 · DOI
  51. Hajak, 1999, A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience, Drug Saf, 21, 457, 10.2165/00002018-199921060-00003 · DOI · Paper page
  52. Hall, 2000, Symptoms of stress and depression as correlates of sleep in primary insomnia, Pyschosom Res, 62, 227
  53. Hansen, 2001, Effects of GABA(A) receptor partial agonists in primary cultures of cerebellar granule neurons and cerebral cortical neurons reflect different receptor subunit compositions, Br J Pharmacol, 133, 539, 10.1038/sj.bjp.0704121 · doi:10.1038/sj.bjp.0704121
  54. Hindmarch, 2001, Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening, Hum Psychopharmacol, 16, 159, 10.1002/hup.282 · DOI
  55. Hindmarch, 2005, Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours post dose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening, Sleep, 28, A245
  56. Hirai, 2005, Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats, J Biol Rhythms, 20, 27, 10.1177/0748730404269890 · DOI
  57. Hirshkowitz, 2004, Normal human sleep: An overview, Med Clin North Am, 88, 551, 10.1016/j.mcna.2004.01.001 · DOI · Paper page
  58. Jia, 2005, An extrasynaptic GABAA receptor mediates tonic inhibition in thalamic VB neurons, J Neurophysiol, 94, 4491, 10.1152/jn.00421.2005 · DOI · Paper page
  59. Jochelson, 2004, Efficacy of indiplon in inducing and maintaining sleep in patients with chronic sleep maintenance insomnia, Sleep, 27, A262
  60. Jones, 2000, Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner, Cancer Lett, 151, 133, 10.1016/S0304-3835(99)00394-8 · DOI
  61. Kantor, 2002, Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift, Brain Res, 943, 105, 10.1016/S0006-8993(02)02698-7 · DOI
  62. Katz, 2002, The relationship between insomnia and health-related quality of life in patients with chronic illness, J Fam Pract, 51, 229
  63. Krystal, 2003, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793 · DOI · Paper page
  64. Lancel, 1997, The GABA(A) agonist THIP increases non-REM sleep and enhances non-REM sleep-specific delta activity in the rat during the dark period, Sleep, 20, 1099, 10.1093/sleep/20.12.1099 · DOI
  65. Lancel, 2000, Gamma-aminobutyric acid(A) (GABA(A)) agonist 4,5,6, 7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol persistently increases sleep maintenance and intensity during chronic administration to rats, J Pharmacol Exp Ther, 293, 1080, 10.1016/S0022-3565(24)39335-8 · DOI
  66. Lancel, 1996, Role of GABAA receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats, Neuropsychopharmacology, 15, 63, 10.1016/0893-133X(95)00157-9 · DOI
  67. Lancel, 2001, Effect of the GABAA agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects, Am J Physiol Endocrinol Metab, 281, 130, 10.1152/ajpendo.2001.281.1.E130 · DOI
  68. Lancel, 2005, The GABAA agonist gaboxadol improves subjective and objective sleep quality in elderly subjects, Sleep, 28, A234
  69. Lankford, 2005, Efficacy and tolerability of indiplon-MR in elderly patients with chronic insomnia: results of a double-blind, placebo-controlled, 2-week trial, Sleep, 28, A230
  70. Lavie, 1986, Differential effects of awakening from REM and NONREM sleep on dichotic listening performance as a function of handedness, Int J Neurosci, 30, 37, 10.3109/00207458608985653 · doi:10.3109/00207458608985653
  71. Lavie, 1997, Melatonin: role in gating nocturnal rise in sleep propensity, J Biol Rhythms, 12, 657, 10.1177/074873049701200622 · DOI · Paper page
  72. Legangneux, 2005, Zolpidem modified-release 6.25 mg and double dose 12.5 mg have no residual effects on central nervous system integrative capacity, sensorimotor and psychomotor performance, and immediate and delayed memory recall in healthy elderly subjects, Sleep, 28, A245
  73. Leger, 2005, An international survey of insomnia: under-recognition and under-treatment of a polysymptomatic condition, Curr Med Res Opin, 21, 1785, 10.1185/030079905X65637 · DOI · Paper page
  74. Leger, 2006, Professional correlates of insomnia, Sleep, 29, 171
  75. Lerchl, 1995, Circadian and ultradian variations of pituitary and pineal hormones in normal men: evidence for a link between melatonin, gonadotropin, and prolactin secretion, J Pineal Res, 18, 41, 10.1111/j.1600-079X.1995.tb00138.x · DOI
  76. Lu, 2000, Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep, J Neurosci, 20, 3830, 10.1523/JNEUROSCI.20-10-03830.2000 · DOI · Paper page
  77. Lu, 2002, Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep, J Neurosci, 22, 4568, 10.1523/JNEUROSCI.22-11-04568.2002 · DOI · Paper page
  78. Lund, 2005, The pharmacokinetic properties of gaboxadol, a new hypnotic, in young and elderly men, Sleep, 28, A48
  79. Luscher, 2004, Regulation of GABAA receptor trafficking, channel activity, and functional plasticity of inhibitory synapses, Pharmacol Ther, 102, 195, 10.1016/j.pharmthera.2004.04.003 · DOI · Paper page
  80. Lustberg, 2000, Depression and insomnia: questions of cause and effect, Sleep Med Rev, 4, 253, 10.1053/smrv.1999.0075 · DOI · Paper page
  81. Mathias, 2001, The GABA(A) agonist gaboxadol improves the quality of post-nap sleep, Psychopharmacology (Berlin), 157, 299, 10.1007/s002130100819 · DOI
  82. Mathias, 2001, The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects, Neurobiol Aging, 22, 247, 10.1016/S0197-4580(00)00232-3 · DOI
  83. Mathias, 2004, Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects, Neuropsychopharmacology, 30, 833, 10.1038/sj.npp.1300641 · DOI
  84. McKernan, 1996, Which GABAA-receptor subtypes really occur in the brain?, Trends Neurosci, 19, 139, 10.1016/S0166-2236(96)80023-3 · DOI · Paper page
  85. McKernan, 2000, Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype, Nat Neurosci, 3, 587, 10.1038/75761 · DOI · Paper page
  86. McMahon, 2005, Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys, Psychopharmacology (Berlin), 178, 400, 10.1007/s00213-004-2022-4 · DOI
  87. Melton, 2005, Eszopiclone for insomnia, Ann Pharmacother, 39, 1659, 10.1345/aph.1G179 · DOI
  88. Merica, 1998, Spectral characteristics of sleep EEG in chronic insomnia, Eur J Neurosci, 10, 1826, 10.1046/j.1460-9568.1998.00189.x · DOI · Paper page
  89. Mignot, 2002, Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders, Nat Neurosci 5 Suppl, 1071, 10.1038/nn944 · DOI · Paper page
  90. Millan, 2003, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways, J Pharmacol Exp Ther, 306, 954, 10.1124/jpet.103.051797 · DOI · Paper page
  91. Mitler, 2000, Nonselective and selective benzodiazepine receptor agonists-where are we today?, Sleep, 23, 39
  92. Miyamoto, 2004, The sleep-promoting action of ramelteon (TAK-375) in freely moving cats, Sleep, 27, 1319, 10.1093/sleep/27.7.1319 · DOI
  93. Mody, 2004, Diversity of inhibitory neurotransmission through GABA(A) receptors, Trends Neurosci, 27, 569, 10.1016/j.tins.2004.07.002 · DOI · Paper page
  94. Mohler, 2002, A new benzodiazepine pharmacology, J Pharmacol Exp Ther, 300, 2, 10.1124/jpet.300.1.2 · DOI · Paper page
  95. Neubauer, 2005, Indiplon: the development of a new hypnotic, Expert Opin Investig Drugs, 14, 1269, 10.1517/13543784.14.10.1269 · DOI
  96. Nusser, 1998, Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells, J Neurosci, 18, 1693, 10.1523/JNEUROSCI.18-05-01693.1998 · DOI · Paper page
  97. Patat, 2001, Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent, Hum Psychopharmacol, 16, 369, 10.1002/hup.310 · DOI
  98. Perlis, 2001, Beta EEG activity and insomnia, Sleep Med Rev, 5, 363, 10.1053/smrv.2001.0151 · DOI · Paper page
  99. Petroski, 2006, Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit containing GABAA receptors, J Pharmacol Exp Ther, 317, 369, 10.1124/jpet.105.096701 · DOI
  100. Puia, 2001, Glial-neuronal interactions: a crescendo in the degree of CNS complexity, Trends Pharmacol Sci, 22, 498, 10.1016/S0165-6147(00)01856-3 · doi:10.1016/s0165-6147(00)01856-3
  101. Rajaratnam, 2004, Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans, J Physiol, 561, 339, 10.1113/jphysiol.2004.073742 · DOI · Paper page
  102. Roehrs, 1994, Sedative, memory, and performance effects of hypnotics, Psychopharmacology (Berlin), 116, 130, 10.1007/BF02245054 · DOI
  103. Roehrs, 2005, Zolpidem modified-release objectivity and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia, Sleep, 28, A244
  104. Rogers, 2001, Neuroimmunologic aspects of sleep and sleep loss, Semin Clin Neuropsychiatry, 6, 295, 10.1053/scnp.2001.27907 · DOI
  105. Rogowski, 2002, NBI-34060 (a non-benzodiazepine sedative-hypnotic): lack of a pharmacokinetic gender effect, Sleep, 25, A415
  106. Roth, 1999, Melatonin promotes osteoblast differentiation and bone formation, J Biol Chem, 274, 22041, 10.1074/jbc.274.31.22041 · DOI · Paper page
  107. Roth, 2005, Efficacy and safety of indiplon-IR in adults with chronic insomnia characterized by prolonged nighttime awakenings with difficulty returning to sleep, Sleep, 28, A229
  108. Rush, 1999, Zaleplon and triazolam in humans: acute behavioral effects and abuse potential, Psychopharmacology (Berlin), 145, 39, 10.1007/s002130051030 · DOI
  109. Sanna, 2002, Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes, Eur J Pharmacol, 451, 103, 10.1016/S0014-2999(02)02191-X · DOI · Paper page
  110. Saper, 2001, The sleep switch: hypothalamic control of sleep and wakefulness, Trends Neurosci, 24, 726, 10.1016/S0166-2236(00)02002-6 · DOI · Paper page
  111. Saper, 2005, Homeostatic, circadian, and emotional regulation of sleep, J Comp Neurol, 493, 92, 10.1002/cne.20770 · DOI · Paper page
  112. Sateia, 2004, Insomnia, Lancet, 364, 1959, 10.1016/S0140-6736(04)17480-1 · DOI · Paper page
  113. Saxena, 1994, Assembly of GABAA receptor subunits: role of the delta subunit, J Neurosci, 14, 7077, 10.1523/JNEUROSCI.14-11-07077.1994 · DOI · Paper page
  114. Scharf, 1994, A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia, J Clin Psychiatry, 55, 192
  115. Schultz, 1981, Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound, Acta Pharmacol Toxicol (Copenh), 49, 116, 10.1111/j.1600-0773.1981.tb00879.x · doi:10.1111/j.1600-0773.1981.tb00879.x
  116. Seiden, 2005, Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia in an elderly population, Sleep, 28, A228
  117. Semyanov, 2004, Tonically active GABAA receptors: Modulating gain and maintaining the tone, Trends Neurosci, 27, 262, 10.1016/j.tins.2004.03.005 · DOI · Paper page
  118. Sharpley, 1994, Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors, Neuropharmacology, 33, 467, 10.1016/0028-3908(94)90077-9 · DOI
  119. Silber, 2005, Chronic insomnia, N Engl J Med, 353, 803, 10.1056/NEJMcp043762 · DOI
  120. Smith, 2001, Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux, Mol Pharmacol, 59, 1108, 10.1124/mol.59.5.1108 · DOI
  121. Staner, 2005, Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring, Psychopharmacology (Berlin), 181, 790, 10.1007/s00213-005-0082-8 · DOI
  122. Stepanski, 1988, Daytime alertness in patients with chronic insomnia compared with controls, Sleep, 11, 54, 10.1093/sleep/11.1.54 · DOI · Paper page
  123. Steriade, 2004, Slow-wave sleep: serotonin, neuronal plasticity, and seizures, Arch Ital Biol, 142, 359
  124. Stickgold, 1998, Sleep: off-line memory reprocessing, Trends Cogn Sci, 2, 484, 10.1016/S1364-6613(98)01258-3 · DOI · Paper page
  125. Storustovu, 2003, Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity, Eur J Pharmacol, 467, 49, 10.1016/S0014-2999(03)01603-0 · DOI
  126. Storustovu, 2005, Pharmacological characterisation of agonists at d containing GABAA receptors: functional selectivity for extrasynaptic receptors is dependent on absence of g2, J Pharmacol Exp Ther, 10.1124/jpet.105.092403 · DOI · Paper page
  127. Sullivan, 2004, Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor, J Pharmacol Exp Ther, 311, 537, 10.1124/jpet.104.071282 · DOI
  128. Terzano, 2003, New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon, Drug Saf, 26, 261, 10.2165/00002018-200326040-00004 · DOI · Paper page
  129. Terzolo, 1993, Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women, Clin Endocrinol, 39, 185, 10.1111/j.1365-2265.1993.tb01772.x · DOI
  130. Trachsel, 1990, Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule, Neuropsychopharmacology, 3, 11
  131. Tripodi, 2004, Pharmacological effects of melatonin on reproductive activity: experimental bioimplants with sustained-release polymeric systems, Clin Exp Obstet Gynecol, 31, 117
  132. Van, 2001, Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers, Psychopharmacology (Berlin), 154, 189, 10.1007/s002130000633 · DOI
  133. Van, 2001, Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus, Am J Physiol Regul Integr Comp Physiol, 280, R1582, 10.1152/ajpregu.2001.280.5.R1582 · DOI
  134. Van Dongen, 2003, Investigating the interaction between the homeostatic and circadian processes of sleep–wake regulation for the prediction of waking neurobehavioral performance, J Sleep Res, 12, 181, 10.1046/j.1365-2869.2003.00357.x · DOI · Paper page
  135. Varkevisser, 2005, Chronic insomnia and performance in a 24-h constant routine study, J Sleep Res, 14, 49, 10.1111/j.1365-2869.2004.00414.x · DOI
  136. Viola, 2002, Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers, Clin Neurophysiol, 113, 429, 10.1016/S1388-2457(02)00014-7 · DOI
  137. Voshaar, 2004, Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study1, Eur Neuropsychopharmacol, 14, 301, 10.1016/j.euroneuro.2003.09.007 · DOI
  138. Voss, 2003, Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance, Eur J Pharmacol, 482, 215, 10.1016/j.ejphar.2003.10.007 · DOI
  139. Wafford, 2005, GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?, Curr Opin Pharmacol, 5, 1, 10.1016/j.coph.2004.08.006 · DOI
  140. Wafford, 1993, Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes, Mol Pharmacol, 43, 240
  141. Wagner, 2000, Non-benzodiazepines for the treatment of insomnia, Sleep Med Rev, 4, 551, 10.1053/smrv.2000.0126 · DOI
  142. Walker, 2005, A refined model of sleep and the time course of memory formation, Behav Brain Sci, 28, 51, 10.1017/S0140525X05000026 · DOI · Paper page
  143. Walsh, 2000, Eight weeks of non-nightly use of zolpidem for primary insomnia, Sleep, 23, 1087, 10.1093/sleep/23.8.1h · DOI · Paper page
  144. Walsh, 2000, A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia, Sleep Med, 1, 41, 10.1016/S1389-9457(99)00006-4 · DOI
  145. Walsh, 2004, Treatment of primary insomnia for five weeks with indiplon-IR, Sleep, 27, A259
  146. Whiting, 1999, Molecular and functional diversity of the expanding GABA-A receptor gene family, Ann N Y Acad Sci, 868, 645, 10.1111/j.1749-6632.1999.tb11341.x · DOI · Paper page
  147. World Health Organization Expert Committee on Drug Dependence. (2003). Thirty-third report, 915 World Health Organ Tech Rep Ser 915, pp. 1-26.
  148. Yous, 1992, Novel naphthalenic ligands with high affinity for the melatonin receptor, J Med Chem, 35, 1484, 10.1021/jm00086a018 · DOI · Paper page
  149. Yukuhiro, 2004, Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys, Brain Res, 1027, 59, 10.1016/j.brainres.2004.08.035 · DOI
  150. Zammit, 1999, Quality of life in people with insomnia, Sleep, 22, S379
  151. Zammit, 2005, Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia, Sleep, 28, A228
  152. Zeman, 2005, Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile, Life Sci, 76, 1795, 10.1016/j.lfs.2004.08.034 · DOI
  153. Zhdanova, 2004, Advances in the management of insomnia, Expert Opin Pharmacother, 5, 1573, 10.1517/14656566.5.7.1573 · DOI

Cited by

See all 166

Metadata

Authors
Ebert, B., Wafford, K. A., & Deacon, S.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2006-12
Volume
112
Issue
3
Pages
612-629
ISSN
0163-7258 (ISSN-L)
OpenAlex
W1997416795
Cited by
166
References
33
FWCI
17.74
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treating insomnia: Current and investigational pharmacological approaches. https://app.cochat.ai/papers/10.1016/j.pharmthera.2005.04.014
The paper
Ebert, B., Wafford, K. A., & Deacon, S. (2006). Treating insomnia: Current and investigational pharmacological approaches. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2005.04.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.